New buy in $NOVO B (+2,58 %) and $1SXP (+1,9 %) a little $D05 (-0,03 %) out and an ETF liquidated. Novo clearly lagged behind this year$LLY (+0,83 %) Y , partly because it was doing quite well before, but also for other reasons. In addition to my article on diabetes, in which I shed light on the company's capital structure, which I find extremely interesting, I am hoping for further confirmation through new strategic positioning outside the insulin and obesity business. I am of the opinion that the company is excellently positioned to divert the cash flows from the Ozempic business into innovative products and various projects. It would be desirable for the management to further strengthen this course. The team looks extremely promising and the company could potentially develop into a strong pharmaceutical investment.
Schott Pharma
Price
Discussion sur 1SXP
Postes
3
As every Sunday, the most important news of the last week, as well as dates of the coming week.
All dates of the coming week in the video:
https://youtube.com/shorts/-GNEKzS7H0U?si=MRBZXj7qgSfLEwnk
Monday:
$3333 Evergrande does not meet the conditions for issuing further share certificates. Thus, no solution was found to reduce the debt in the amount of 300 billion USD.
No improvement in business sentiment in Germany. The Ifo index falls for the fifth time in a row. The construction sector in particular is pessimistic about the future.
$SE (-2,34 %) Sea ltd benefits from a possible e-commerce ban for Tiktok in Indonesia, as well as a new release of Free Fire in India, the share can gain significantly.
Tuesday:
Consumer confidence in the U.S. 🇺🇸 has deteriorated more than expected. The markets have fallen further, the recession seems to be an increasingly realistic scenario.
According to $MBG (+0,74 %) Mercedes $BMW (+0,21 %) BMW is the second supplier to receive Stage 3 approval for autonomous driving. $TSLA (+5,05 %) Tesla talks a lot about autonomous driving, but is not as far along in terms of approvals as the two premium manufacturers.
The company $TGT (+3,47 %) Target forced to close nine stores due to runaway thefts. In the USA, retailers have enormous problems with thefts.
Wednesday:
Unlike at the Oktoberfest, Germans currently prefer to save rather than consume. The GfK forecasts a further decline in consumer confidence for October.
Thursday:
IPO of $1SXP (+1,9 %) Schott Pharma seems to be a success. The allotment price was EUR 27 per share, the first price EUR 30.
As expected, inflation came down significantly in September and is now still at 4.5% year-on-year. However, a somewhat smaller decline of 4.6% had been expected. The main reason for the sharp decline compared with the previous month (+6.1%) is the discontinuation of the €9 ticket and the fuel price brake in September of the previous year. Thus, it looks like we have reached the interest rate peak. The current interest rates are probably sufficient to push inflation back toward the 2% target.
Friday:
$NKE (+2,62 %) Nike delivers figures yesterday. Sales were slightly below expectations, but earnings were above expectations. Earnings per share rose to $0.94 in the quarter, up from just $0.75 expected. Also $ADS (+1,37 %) Adidas and $PUM (-1,22 %) Puma also benefit from the figures.
https://stock3.com/news/nike-umsatz-enttaeuscht-gewinn-ueberzeugt-aktie-im-plus-13286823
Inflation is also easing significantly in the euro zone as a whole, and much more strongly than expected. Inflation was 4.3% year-on-year. A rate of 4.6% had been expected. This is 0.9 percentage point lower than in August. There is much to suggest that the ECB will pause on interest rates in October.
Monday: 16:00 Manufacturing (USA)
Tuesday: 08:30 Inflation data (Switzerland)
Wednesday: 11:00 Retail Sales (EU)
Thursday: 08:00 Trade Balance (DE)
Friday: 06:30 Interest rate decision (India)
MEDICAL DEVICES $1SXP (+1,9 %)
Is Schott Pharma worth the entry?
With an issue volume of up to 987 million euros, Schott Pharma promises to be the largest IPO of the year in Germany. The share (29.00 euros; DE000A3ENQ51), which is already tradable at brokers as of its release, can still be subscribed to until September 27 in the range of 24.50 to 28.50 euros.
The specialist in drug storage and delivery systems is active in two very high-growth areas (mRNA therapies and GLP-1 drugs). Even with the expected allocation at the upper end of the range, the stock is attractively valued even compared to the competition.
First, on the numbers: Including the greenshoe, up to 34.6 million of the 150.6 million shares held by the parent company, Mainz-based Schott AG, which is part of the Carl Zeiss Foundation, will be listed on the Frankfurt Stock Exchange. Schott Pharma will not receive any fresh capital. At full allotment, the free float is 23%, although Qatar Holding has agreed to acquire up to 4.99% of the securities for 200 million euros. In total, the company is valued at 3.69 billion to 4.29 billion euros at the IPO - so this is a heavyweight with ambitions for inclusion in the DAX family landing on the trading floor.
Schott Pharma develops and produces glass syringes, polymer syringes, vials and ampoules for more than 1,800 customers worldwide. Every minute, around 25,000 injections are administered worldwide with the help of Schott Pharma products. The market for injectable drugs is expected to grow by more than 8% annually until 2026. The Mainz-based company itself is expected to generate sales of around EUR 890 million this year (as of September 30) with EBITDA of an estimated EUR 250 million (margin: 28%).
In the medium term, the company, which mainly benefits from structural growth drivers such as the use of special packaging for mRNA therapies (keyword: cooling below 100 degrees Celsius) and GLP-1 drugs (keyword: diabetes, obesity), is targeting sales growth in the low 10% range with an EBITDA margin of over 30%. Both are readily achievable, assuming sales growth of 12% p.a. with earnings growth of 19% p.a. through 2024/25.
Schott Pharma is less comparable with Gerresheimer, which is somewhat more diversified, but rather with pure medical specialists such as the Italian Stevanato or the US Becton Dickinson. According to calculations, this comparison turns out favorably: Schott Pharma is valued even at the upper end of the subscription range only at about 17 times the future expected EBITDA. In the case of the competitors, this ratio is significantly higher at 25 times EBITDA, with their EPS growth estimated to be significantly lower (Stevanato: 13% p. a.; Becton Dickinson: 6% p. a.). The situation is similar for the P/E ratio: Schott Pharma is calculated at 25 times expected earnings for 2023/24, Becton Dickinson at 42 times and Stevanato at 40 times. Since the books were oversubscribed just a few hours after opening, I assume an allocation at the upper end of the range.
I subscribed because of the growth opportunities of the attractive valuation due to a nearly net debt-free balance sheet.
Titres populaires
Meilleurs créateurs cette semaine